Mumbai, July 8 -- Exblifep (cefepime/enmetazobactam), a novel combination antibiotic for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gram-negative bacterial pathogens, subject to regulatory approval by the Ministry of Health of the Russian Federation.

Exblifep is a carbapenem-sparing antibiotic developed to address the growing clinical challenge posed by extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria in serious hospital infections. The product is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is included in IDSA and EUCAST treatment guidelines, and is the firs...